9th DDR Inhibitors Summit 2026

 

The 9th DDR Inhibitors Summit returns to Boston in 2026 as the leading event uniting biopharma, biotech, and academia to advance next-generation DNA Damage Response (DDR)-targeted therapies beyond PARP.

With growing clinical momentum for ATR, CHK1/2, WEE1, and DNA-PK inhibitors, this 3-day meeting delivers cutting-edge insights on biomarker-driven discovery, translational strategy, and combination approaches.

Featuring 30+ expert speakers from Artios Pharma, AstraZeneca, Merck, and others, attendees will benchmark programs, explore innovations, and network with global DDR leaders shaping the future of precision oncology through synthetic lethality and safer, more effective cancer treatments.

More Info

---

---